Literature DB >> 17172618

Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging.

Marwan N Sabbagh1, Flora Shah, Richard T Reid, Lucia Sue, Donald J Connor, Lars Kristofer N Peterson, Thomas G Beach.   

Abstract

BACKGROUND: Neurochemical and pathologic studies show that mild cognitive impairment (MCI) is frequently a transitional state between normal aging and Alzheimer disease (AD). Neuropathologic sample sizes have been limited because relatively few individuals with MCI die before dementia develops. Decreased neocortical nicotinic receptor binding is characteristic of AD but has not been investigated in subjects with MCI.
OBJECTIVE: To assess nicotinic receptor binding and pathologic differences in control subjects with no dementia (ND) and in subjects with clinically and pathologically described MCI or Alzheimer disease.
DESIGN: This was a clinicopathologic analysis. Subjects with ND had no demonstrable cognitive or functional impairment. Subjects with MCI met Petersen clinical criteria for single- or multiple-domain amnestic MCI and died before the disorder progressed to AD. Subjects with AD met National Institute for Neurological Diseases and Stroke/Alzheimer's Disease and Related Disorders Association clinical criteria for AD. All subjects underwent a complete diagnostic and semiquantitative neuropathologic examination. Data were examined after both clinical and histopathologic classification of subjects.
SETTING: Sun Health Research Institute Brain Donation Program, and Arizona Alzheimer Disease Center. PARTICIPANTS: Twenty-one control subjects with ND, 8 subjects with MCI, and 70 subjects with AD, prospectively followed up to autopsy. MAIN OUTCOME MEASURES: Nicotinic acetylcholine receptor binding value, total tangle density, total plaque density, and Braak stage.
RESULTS: At the last examination before death, subjects with AD were significantly younger, less educated, and more cognitively and globally impaired compared with subjects with ND. When categorized by clinical diagnosis, MCI was always intermediate between ND and AD. On the whole, MCI was pathologically intermediate between ND and AD for senile plaque density, neurofibrillary tangle density, and Braak stage, but some subjects with MCI lacked neuritic plaques entirely. Binding for nicotinic acetylcholine receptors did not differ between the ND and MCI groups, but it was significantly less in the AD group.
CONCLUSIONS: Most MCI may be considered a transitional state between ND and AD clinically and neuropathologically, but in some MCI cases there is lack of neuritic plaques, and, therefore, it cannot be considered early AD. Nicotinic receptor binding seems to be lost during the transition from MCI to AD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17172618     DOI: 10.1001/archneur.63.12.1771

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  19 in total

Review 1.  Mild cognitive impairment: pathology and mechanisms.

Authors:  Elliott J Mufson; Lester Binder; Scott E Counts; Steven T DeKosky; Leyla de Toledo-Morrell; Stephen D Ginsberg; Milos D Ikonomovic; Sylvia E Perez; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-11-19       Impact factor: 17.088

Review 2.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

3.  Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease.

Authors:  Cassia R Overk; Christian C Felder; Yuan Tu; Doug A Schober; Kelly R Bales; Joanne Wuu; Elliott J Mufson
Journal:  J Chem Neuroanat       Date:  2010-03-27       Impact factor: 3.052

4.  The effects of aging vs. α7 nAChR subunit deficiency on the mouse brain transcriptome: aging beats the deficiency.

Authors:  Merav Kedmi; Avi Orr-Urtreger
Journal:  Age (Dordr)       Date:  2010-06-05

Review 5.  Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.

Authors:  Yunqi Xu; Junqiang Yan; Peng Zhou; Jiejie Li; Huimin Gao; Ying Xia; Qing Wang
Journal:  Prog Neurobiol       Date:  2012-02-25       Impact factor: 11.685

Review 6.  Nicotine and networks: Potential for enhancement of mood and cognition in late-life depression.

Authors:  Jason A Gandelman; Paul Newhouse; Warren D Taylor
Journal:  Neurosci Biobehav Rev       Date:  2017-08-30       Impact factor: 8.989

7.  Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment.

Authors:  Charles H Adler; John N Caviness; Marwan N Sabbagh; Holly A Shill; Donald J Connor; Lucia Sue; Virgilio G H Evidente; Erika Driver-Dunckley; Thomas G Beach
Journal:  Acta Neuropathol       Date:  2010-09-14       Impact factor: 17.088

8.  Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease.

Authors:  Pamela E Potter; Paula K Rauschkolb; Yoga Pandya; Lucia I Sue; Marwan N Sabbagh; Douglas G Walker; Thomas G Beach
Journal:  Acta Neuropathol       Date:  2011-05-01       Impact factor: 17.088

9.  Functional integrity of thalamocortical circuits differentiates normal aging from mild cognitive impairment.

Authors:  Jose L Cantero; Mercedes Atienza; German Gomez-Herrero; Abel Cruz-Vadell; Eulogio Gil-Neciga; Rafael Rodriguez-Romero; David Garcia-Solis
Journal:  Hum Brain Mapp       Date:  2009-12       Impact factor: 5.038

10.  Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease.

Authors:  Milos D Ikonomovic; Lynn Wecker; Eric E Abrahamson; Joanne Wuu; Scott E Counts; Stephen D Ginsberg; Elliott J Mufson; Steven T Dekosky
Journal:  Arch Neurol       Date:  2009-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.